Bionano reiterates $31M-$33M 2026 revenue guidance while targeting adjusted EBITDA neutrality by end of 2027

• “Bionano delivered a strong third quarter,” said (Chairman, Interim CEO, Interim President & Interim Principal Financial Officer Albert Luderer), adding that results reflected “the continued global utilization of optical genome mapping, or OGM.”

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.